<DOC>
	<DOCNO>NCT01688336</DOCNO>
	<brief_summary>This single arm , multi-center phase II clinical trial ass safety efficacy FOLFIRINOX first-line setting patient unresectable locally advanced ( ULA ) borderline resectable ( BR ) pancreatic cancer .</brief_summary>
	<brief_title>FOLFIRINOX Unresectable Locally Advanced Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description>FOLFIRINOX regimen recently present international oncology meeting represent new standard treatment metastatic pancreatic cancer select patient . With improved overall survival ( OS ) response rate ( RR ) metastatic setting , hypothesize patient less tumor burden , regimen safe well tolerate , improve OS , progression free survival ( PFS ) , RR , improve resectability rate , compare historical data standard single agent gemcitabine therapy unresectable locally advanced ( ULA ) patient standard radiation concurrent 5 flourouracil ( 5FU ) chemotherapy borderline resectable ( BR ) patient . While ULA BR patient eligible present study , primary objective concern ULA patient , plan enroll 45 patient group . Patients meet eligibility criterion consent treated FOLFIRINOX every 2 week ( 1 cycle = 4 week = 2 treatment ) . Patients undergo repeat imaging ( CT MRI ) every 2 cycle reassess resectability tumor . All patient able undergo surgical resection , due insufficient down-staging patient preference , continue protocol-based therapy disease progression , unacceptable toxicity , study withdrawal , death .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Biopsy confirm adenocarcinoma pancreas . Measurable nonmeasurable evaluable ( determine Response Evaluation Criteria Solid Tumors version 1.1 [ RECIST 1.1 ] ) unresectable locally advanced ( ULA ) borderline resectable ( BR ) disease amenable curative intent therapy . Baseline CT abdomen chest ( MRI abdomen ) within 28 day prior initiation FOLFIRINOX require . ECOG performance status 0 1 . No prior chemotherapy chemoradiotherapy pancreatic cancer . Age ≥ 18 year age . Laboratory requirement study entry : Hemoglobin ≥ 10 g/dL ( transfusion acceptable ) ANC ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Creatinine ≤ 1.5 x ULN , creatinine clearance ≥ 50 mL/min ( estimate CockcroftGault measure ) Total bilirubin ≤ 1.5 x ULN AST/ALT ≤ 3 x ULN GGT ≤ 5 x ULN Life expectancy least 6 month . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test perform within 14 day prior initiation FOLFIRINOX . WOCBP men must agree use adequate contraception prior study entry , duration study participation , 8 week end treatment . Before patient registration , write informed consent must give . Local recurrence resectable recurrence pancreatic cancer . Other malignancy within past 3 year except adequately treated cervical vulvar carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior entry permit . Hypersensitivity 5FU , oxaliplatin platinum agent , irinotecan excipients . Known dihydropyrimidine dehydrogenase ( DPD ) enzyme deficiency . Participation investigational drug study within 4 week precede start study treatment . Patients permit participate another investigational drug study treat protocol . Cardiac disease : Congestive heart failure symptom &gt; class II NYHA . Unstable angina ( anginal symptom rest ) new onset angina begin within last 3 month . Myocardial infarction within past 6 month . Cardiac ventricular arrhythmia require antiarrhythmic therapy . History suspect Gilbert 's Disease ( baseline testing require ) . Baseline peripheral neuropathy/paresthesia grade ≥ 1 . Active hepatitis B , unless patient stable med least 2 month ( baseline testing require ) . Active clinically serious infection ( &gt; grade 2 ) . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 12 week prior first dose FOLFIRINOX . Evidence history bleed diathesis coagulopathy . NOTE : If therapeutic anticoagulation require , investigator encourage switch patient ( maintain ) low molecular weight heparin trial . Major surgery , open biopsy significant traumatic injury within 8 week first study drug . A core pancreatic liver biopsy preclude patient study . Unable unwilling discontinue use ketoconazole St John 's wort . Use CYP3A4 enzymeinducing drug strong CYP3A4 inhibitor discourage , contraindicate . Active drug alcohol abuse . Pregnant lactating woman . Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Phase II</keyword>
	<keyword>FOLFIRINOX</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Regimen</keyword>
	<keyword>First-line</keyword>
	<keyword>Resectable</keyword>
	<keyword>Borderline</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>5FU</keyword>
	<keyword>Lineberger</keyword>
	<keyword>University North Carolina</keyword>
</DOC>